ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Codex Labs to Represent at 2025 European Academy of Dermatology and Venereology Congress

Codex Labs to Represent at 2025 European Academy of Dermatology and Venereology Congress

Paris, France - September 17th, 2025 - Codex Labs, a biotech skincare company specializing in microbiome-friendly solutions for chronic skincare conditions, is honored to participate in the 2025 European Academy of Dermatology and Venereology (EADV). From September 17th to 20th in Paris, France, over 17,000 individuals from all around the world will gather to discuss and learn about the prevention, diagnosis, and treatment of skin and venereal diseases.

This multi-day event will feature keynote speakers, EADV games, a networking symposium, and workshops highlighting the latest research and science in dermatology and venereology. As an exhibitor at this year’s EADV in Paris, the event will also allow Codex Labs to establish its brand within the EU dermatology market.

“We are delighted to attend our first EADV congress and introduce Codex Labs as an integrative, plant-biotech brand delivering innovative skin-gut solutions for acne and eczema,” says founder and CEO Dr. Barbara Paldus.

Initially consisting of just six individuals, the EADV has now grown to over 12,000 members worldwide, all with the same purpose: to come together and deepen their understanding of the world of Dermato-Venerology. The EADV fosters an environment in which its members can develop, share, and adopt best practices through collaboration, research, and trials.

This year's EADV congress will feature satellite symposia that delve deeper into the topics presented by this year's keynote speakers, as well as industry expert hubs that will facilitate small-group discussions for industry professionals to explore the event’s focal points in greater depth.

Codex Labs is honored to participate in the event and looks forward to showcasing its products and findings. Codex Labs invites all event guests to visit their team’s exhibition booth to learn more about its most recent skincare breakthroughs and receive product samples of Shaant topicals and supplements for treating acne and Bia topicals and supplements for treating eczema.

Event Details:

  • Dates: September 17th - 20th, 2025

    • September 17th, 8:30 am - 5:30 pm CET

      • Codex Labs exhibition open from 12:00 pm - 5:30 pm CET

    • September 18th, 8:30 am - 5:30 pm CET

      • Codex Labs exhibition open from 9:00 am - 5:30 pm CET

    • September 19th, 8:30 am - 5:30 pm CET

      • Codex Labs exhibition open from 9:00 am - 5:30 pm CET

    • September 20th, 8:30 am - 5:30 pm CET

      • Codex Labs exhibition open from 9:00 am - 12:00 pm CET

  • Location: Paris Expo Porte de Versailles 1 Pl. de la Porte de Versailles, 75015 Paris

For more information about Codex Labs and its products, please visit www.codexlabscorp.com. If you are interested in learning more about Codex Labs’ participation in EADV, please contact annakate.womack@otterpr.com.

About Codex Labs:

Based in Silicon Valley and led by scientist Dr. Barb Paldus, Codex Labs is committed to creating highly effective, clinically proven, microbiome-supporting skin-gut-brain-biome solutions that contain potent, biotech-derived plant-based actives. Codex Labs’ products focus on restoring/protecting the skin barrier, managing inflammation, and addressing skin conditions associated with eczema, acne, rosacea, and psoriasis. The brand has been heralded by integrative dermatologists and naturopathic doctors for creating the next generation of effective, vegan, cruelty-free, and sustainable plant-based solutions.

Media Contact
Company Name: Otter Public Relations
Contact Person: Anna Kate Womack
Email: Send Email
City: ORLANDO
State: FL
Country: United States
Website: www.otterpr.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.